Abstracts tagged "rheumatoid arthritis (RA) and tofacitinib"

Abstract Number: 2785 • 2017 ACR/ARHP Annual Meeting
Serious Infections Associated with Tofacitinib in Rheumatoid Arthritis Patients Previously Treated with Methotrexate
Marina Amaral de Avila Machado¹, Cristiano S. Moura², Steve Ferreira Guerra¹, Jeffrey R. Curtis³, Michal Abrahamowicz⁴, Hassan Behlouli¹ and Sasha Bernatsky⁵, ¹Department of Medicine, McGill University Health Centre, Montreal, QC, Canada, ²1Division of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ³Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Medicine, McGill University Health Centre, Montreak, QC, Canada, ⁵Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Little is known about the real-world safety of tofacitinib, an oral Janus kinase inhibitor. We compared serious infections associated with tofacitinib, disease-modifying antirheumatic drugs…
Abstract Number: 2600 • 2016 ACR/ARHP Annual Meeting
Tofacitinib Is Associated with an Impaired Function of NK Cells and a Defective Immunosurveillance Against B-Cell Lymphomas
Gaetane Nocturne^1,2, Farhad Tahmasebi³, Saida Boudaoud⁴, Bineta Ly⁵ and Xavier Mariette^6,7, ¹Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ²INSERM U1184, Université Paris Sud, Le Kremlin Bicêtre, France, ³INSERM 1184, Paris Sud University, Le Kremlin Bicetre, France, ⁴INSERM U1184, Paris Sud University, Le Kremlin Bicêtre, France, ⁵INSERM U1184, Paris Sud University, Kremlin Bicetre, France, ⁶Department of Rheumatology, APHP - Hopitaux universitaire Paris Sud, Le Kremlin Bicetre, France, ⁷INSERM U1184, Université Paris-Sud, Paris, France, Le Kremlin Bicetre, France
Background/Purpose: Disease activity is the main risk factor for developing lymphoma in patients with rheumatoid arthritis (RA). However, the impact of immunosuppressive drugs remains an…
Abstract Number: 3090 • 2016 ACR/ARHP Annual Meeting
Inflammation Detected with Modern Sensitive MRI Analysis Demonstrates That Therapeutic Response As Early As One Month Predicts 12-Month Radiographic Progression: Data from a Study Using Tofacitinib and Methotrexate in Early RA
Philip G. Conaghan¹, Michael A Bowes², Mikkel Østergaard³, Gwenael Guillard², Douglass Chapman⁴, Amy Stein⁵, John Andrews⁴, Zhiyong Xie⁶, Andrew Koenig⁷, Koshika Soma⁴ and Bethanie Wilkinson⁶, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Imorphics Ltd, Manchester, United Kingdom, ³Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ⁴Pfizer Inc, New York, NY, ⁵Biostatistics, Quintiles, Morrisville, NC, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. A novel automated quantification method for RA MRI-detected pathology using statistical shape…
Abstract Number: 81 • 2016 ACR/ARHP Annual Meeting
Understanding the Importance of a Patient’s Role in the Management of RA: Physician- and Patient-Based Survey
Ara Dikranian¹, James Galloway², Joern Kekow³, Cristiano A.F Zerbini⁴, Maria de la Vega⁵, Gavin Lee⁶, Anna Maniccia⁷, Eustratios Bananis⁸, Dario Ponce de Leon⁹ and Allan Gibofsky¹⁰, ¹San Diego Arthritis Medical Clinic, San Diego, CA, ²King's College, and King´s College Hospital, London, United Kingdom, ³University of Magdeburg, Clinic of Rheumatology, Magdeburg, Germany, ⁴Centro Paulista de Investigação Clinica, São Paulo, Brazil, ⁵CEIM Investigaciones Médicas, Buenos Aires, Argentina, ⁶Hong Kong Sanatorium & Hospital, Hong Kong SAR, China, ⁷Pfizer Inc, New York, NY, ⁸Pfizer Inc, Collegeville, PA, ⁹Pfizer Inc, Lima, Peru, ¹⁰Rheumatology, Weill Cornell Medicine, and Hospital for Special Surgery, New York, NY
Background/Purpose: RA is a chronic, debilitating condition for which there is no cure. To identify and better understand the perspectives of both healthcare providers (HCPs)…
Abstract Number: 1571 • 2016 ACR/ARHP Annual Meeting
Altered Bioenergetics, Mitochondrial Function and Pro-Inflammatory Pathways in RA Synovium in Response to Tofacitinib
Carl Orr¹, Trudy McGarry², Monika Biniecka³, Jennifer McCormick⁴, Ursula Fearon⁵ and Douglas J. Veale¹, ¹Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin 4, Ireland, ²St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin 4, Ireland, ³St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland, ⁴Department of Rheumatology, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland, ⁵Trinity College Dublin, Department of Molecular Rheumatology, Trinity College Dublin, Dublin, Ireland
Background/Purpose: Rheumatoid arthritis (RA) is a chronic joint disease, characterised by synovial inflammation and destruction of articular cartilage/bone. The Janus-Kinase and Signal Transducer and Activator…
Abstract Number: 1608 • 2016 ACR/ARHP Annual Meeting
Lack of Early Change in Disease Activity Score Predicts the Likelihood of Achieving Low Disease Activity at Month 6: Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naive Patients with Rheumatoid Arthritis
Edward Keystone¹, Ronald F van Vollenhoven², Bethanie Wilkinson³, Lara Fallon⁴, Lie-Ju Hwang⁵, Douglass Chapman⁵, Ryan DeMasi⁵ and Eun Bong Lee⁶, ¹Mount Sinai Hospital, Toronto, ON, Canada, ²Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ³Pfizer Inc, Groton, CT, ⁴Pfizer Canada, Montreal, QC, Canada, ⁵Pfizer Inc, New York, NY, ⁶Seoul National University, Seoul, Korea, Republic of
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Treatment guidelines recommend targeting remission or low disease activity (LDA), herein…
Abstract Number: 1637 • 2016 ACR/ARHP Annual Meeting
Real-World Use of Tofacitinib in Rheumatoid Arthritis: Data from the Swiss Clinical Quality Management RA Registry
Diego Kyburz¹, Myriam Riek², Lisa Herzog³, Almut Scherer³, Cem Gabay⁴, Jean Dudler⁵, Pascal Zufferey⁶ and Axel Finckh⁷, ¹Department of Biomedicine, Experimental Rheumatology, University of Basel, 4051 Basel, Switzerland, ²SCQM foundation, zurich, Switzerland, ³SCQM Foundation, Zurich, Switzerland, ⁴Rheumatology, Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁵Rheumatology, HFR Fribourg - Hôpital Cantonal, Fribourg, Switzerland, ⁶Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland, ⁷Rheumatology Division, University Hospital of Geneva, Geneva, Switzerland
Background/Purpose: The oral Janus kinase inhibitor Tofacitinib (Tofa) has been licensed in Switzerland 2013 for the treatment of patients with moderate to severe rheumatoid arthritis…
Abstract Number: 1643 • 2016 ACR/ARHP Annual Meeting
Tofacitinib: Treatment Outcomes in Seropositive Versus Seronegative Patients in a Phase 3 RA Population
Paul Bird¹, Stephen Hall², Peter Nash³, Carol A Connell⁴, Kenneth Kwok⁵, David Witcombe⁶ and Krishan Thirunavukkarasu⁶, ¹University of New South Wales, Sydney, Australia, Sydney, NSW, Australia, ²Cabrini Health and Monash University, Melbourne, VIC, Australia, ³Department of Medicine, University of Queensland, Brisbane, QLD, Australia, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Australia, Sydney, NSW, Australia
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This study examined response to treatment with tofacitinib 5 mg or 10…
Abstract Number: 2580 • 2016 ACR/ARHP Annual Meeting
Tofacitinib Do Not Get Worse Subclinical Atherosclerosis Despite up-Regulating Serum Cholesterol in Methotrexate-Resistant Active Rheumatoid Arthritis Patients
Kensuke Kume¹, Kanzo Amano², Susumu Yamada¹, Toshikatsu Kanazawa³, Kazuhiko Hatta⁴ and Noriko Kuwaba⁵, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²rheumatology., hiroshima clinic, Hiroshima, Japan, ³rheumatology, hiroshima clinic, hiroshima, Japan, ⁴Rheumatology, Hatta Clinic, Kure, Japan, ⁵Medical Research, Sanki Clinical Link, Hiroshima, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased cardiovascular (CV) risk. We should have strategies for primary cardiovascular　prevention in RA. Tofacitinib (Tofa) could possibly…
Abstract Number: 2593 • 2016 ACR/ARHP Annual Meeting
The Effect of Tofacitinib on Bone Mineral Density in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis
Kensuke Kume¹, Kanzo Amano², Susumu Yamada¹, Toshikatsu Kanazawa³, Kazuhiko Hatta⁴ and Noriko Kuwaba⁵, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²rheumatology., hiroshima clinic, Hiroshima, Japan, ³rheumatology, hiroshima clinic, hiroshima, Japan, ⁴Rheumatology, Hatta Clinic, Kure, Japan, ⁵Medical Research, Sanki Clinical Link, Hiroshima, Japan
Background/Purpose: To analyze the effects of therapy with tofacitinib (Tofa), a Janus kinase inhibitor on the bone mineral density (BMD) of the lumbar spine and…
Abstract Number: 559 • 2015 ACR/ARHP Annual Meeting
Herpes Zoster and Tofacitinib: The Risk of Concomitant Nonbiologic Therapy
Kevin L. Winthrop¹, Jeffrey R. Curtis², Stephen Lindsey³, Hernan Valdez⁴, Haiyun Fan⁵, Lisy Wang⁶, Alan M. Mendelsohn⁵ and Eustratios Bananis⁵, ¹Oregon Health & Science University, Portland, OR, ²The University of Alabama at Birmingham, Birmingham, AL, ³Ochsner Medical Center, Baton Rouge, LA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Patients with RA are at increased risk for herpes zoster (HZ). Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Treatment…
Abstract Number: 566 • 2015 ACR/ARHP Annual Meeting
Genome-Wide Trans-Ancestry Meta-Analysis of Herpes Zoster in RA and Pso Patients Treated with Tofacitinib
Nan Bing¹, HuanYu Zhou¹, BaoHong Zhang¹, John D Bradley², Makoto Nagaoka³, Hernan Valdez⁴, Michael Vincent¹ and James D. Clark¹, ¹Pfizer Inc, Cambridge, MA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Tokyo, Japan, ⁴Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Rates of herpes zoster (HZ) were higher than observed with…
Abstract Number: 571 • 2015 ACR/ARHP Annual Meeting
Malignancy Data in Tofacitinib-Treated Japanese Patients with Rheumatoid Arthritis
Yoshiya Tanaka¹, Tsutomu Takeuchi², Hisashi Yamanaka³, Naonobu Sugiyama M.D., Ph.D⁴, Takunari Yoshinaga⁴, Kanae Togo⁴, Jamie Geier⁵, Mary Boy⁵ and Carol Connell⁵, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ²Keio University School of Medicine, Tokyo, Japan, ³Tokyo Women’s Medical University, Tokyo, Japan, ⁴Pfizer Japan Inc, Tokyo, Japan, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). In the global tofacitinib RA clinical program, rates and types…
Abstract Number: 1225 • 2015 ACR/ARHP Annual Meeting
Long-Term Use of Biological Therapy and Discontinuation Rates in Rheumatoid Arthritis – Real World Patient Data
Laurent Chanroux, Joan Casellas and Fara Mboge, Therapy Watch, Research Partnership, London, United Kingdom
Background/Purpose: Biologics (bDMARDs) have been shown to control disease progression in RA however there is still no cure for the disease and in many cases…
Abstract Number: 1634 • 2015 ACR/ARHP Annual Meeting
The Effects of Glucocorticoids on the Efficacy of Tofacitinib As Monotherapy and in Combination Therapy with Nonbiologic Dmards: An Analysis of Data from Six Phase 3 Studies
Roy Fleischmann¹, Christina Charles-Schoeman², Gerd Burmester³, Cristiano Zerbini⁴, Peter Nash⁵, Kenneth Kwok⁶, Koshika Soma⁷, Alan Mendelsohn⁸ and Eustratios Bananis⁸, ¹Metroplex Clinical Research Center, Dallas, TX, ²University of California, Los Angeles, CA, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Centro Paulista de Investigação Clinica, São Paulo, Brazil, ⁵Nambour Hospital, Sunshine Coast and Department of Medicine, University of Queensland, Queensland, Australia, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Patients with RA often receive concomitant treatment with glucocorticoids (GCs) to control…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].